Atp7B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ATP7B is a copper-transporting P-type ATPase gene that plays a central role in systemic copper homeostasis and is the primary disease gene in Wilson's Disease.12 ATP7B is highly expressed in hepatocytes, where it
supports both copper incorporation into ceruloplasmin and biliary copper excretion. Pathogenic ATP7B variants reduce these functions and drive progressive copper overload with
hepatic and neurologic toxicity.13
¶ Gene and Protein Structure
¶ Chromosomal Location and Gene Organization
The ATP7B gene is located on chromosome 13q14.3 and consists of 21 exons spanning approximately 80 kb of genomic DNA. The gene encodes a transmembrane protein of 1465 amino acids with a molecular weight of approximately 165 kDa.
¶ Protein Domains
ATP7B belongs to the P-type ATPase family (E1-E2 ATPases) and contains several critical functional domains:
- N-terminal metal-binding domain: Contains six copper-binding motifs (CXXC) that sense intracellular copper levels
- Phosphorylation domain (P-domain): Contains the conserved DKTGTLT motif essential for ATP hydrolysis
- ATP-binding domain (A-domain): Responsible for ATP binding and energy transduction
- Transmembrane domain: Forms the channel for copper ion translocation across the membrane
- Actuator domain (A-domain): Involved in conformational changes during the transport cycle
ATP7B is predominantly expressed in:
- Hepatocytes (liver) - highest expression
- Brain (choroid plexus, astrocytes)
- Kidney
- Placenta
- Small intestine
¶ Protein Function and Copper Homeostasis
ATP7B operates through a sophisticated conformational cycle characteristic of P-type ATPases:
- E1 State: ATP7B binds copper ions at the N-terminal sensor domains in the cytoplasm
- ATP Binding: ATP binds to the A-domain, triggering phosphorylation of the P-domain
- Conformational Change: The protein undergoes major structural rearrangement
- E2 State: Copper is released into the trans-Golgi lumen or extracellular space
- Dephosphorylation: The cycle completes, returning the protein to the E1 state
Under physiologic copper conditions, ATP7B performs two essential functions:
- Ceruloplasmin biosynthesis: ATP7B loads six copper atoms onto apoceruloplasmin in the trans-Golgi network, producing functional ceruloplasmin (holo-ceruloplasmin) which is secreted into the bloodstream1
- Biliary copper excretion: With rising intracellular copper, ATP7B traffics toward vesicular/canalicular compartments to facilitate copper export into bile for elimination2
Cellular copper homeostasis requires specialized chaperone proteins:
- CTR1: Copper importer on the cell membrane
- CCS (Copper Chaperone for SOD1): Delivers copper to SOD1
- COX17: Delivers copper to cytochrome c oxidase
- ATOX1: Antisense oxidoreductase 1 - delivers copper to ATP7B/ATP7A
Although ATP7B is classically considered a hepatology gene, its dysfunction has major neurologic consequences via systemic copper dysregulation. Copper spillover from hepatic
failure to maintain homeostasis contributes to deposition and injury in motor and cognitive circuits, especially in the basal ganglia. class="ref-link" data-ref-number="2" data-ref-text="Członkowska A et al., Wilson disease (2018)" title="Członkowska A et al., Wilson disease (2018)">267
Copper accumulation in the brain leads to:
- Movement disorders: Tremor, dystonia, parkinsonism
- Neuropsychiatric symptoms: Depression, anxiety, personality changes
- Cerebellar involvement: Ataxia, dysarthria
- Cognitive impairment: Progressive dementia in advanced cases
The basal ganglia are particularly vulnerable, especially:
- Putamen: Most commonly affected
- Globus pallidus
- Thalamus
- Brainstem nuclei
This pattern can resemble Parkinson's Disease or other progressive neurologic conditions.2
Hundreds of ATP7B pathogenic variants have been reported worldwide, with substantial geographic heterogeneity:
| Variant |
Type |
Prevalence |
| H1069Q |
Missense |
Most common in European populations |
| R778L |
Missense |
Common in East Asian populations |
| A874V |
Missense |
Found in various populations |
| 2299insC |
Frameshift |
Common in some populations |
- Null/null genotypes: Often present with severe hepatic disease
- Residual function variants: May present with primarily neurologic manifestations
- Compound heterozygotes: Variable phenotype depending on allele combination
Variant class and residual transporter activity can influence age at onset and predominant phenotype, but clear one-to-one prediction remains limited.24
¶ Diagnostics and Biomarkers
ATP7B molecular testing is now part of standard workups for suspected Wilson disease when biochemical findings are inconclusive or family screening is needed.13
- Serum ceruloplasmin: Typically low (<20 mg/dL)
- 24-hour urinary copper excretion: Elevated (>100 μg/24h)
- Serum copper: Variable; non-ceruloplasmin-bound "free" copper elevated
- Relative exchangeable copper (REC): New biomarker with high specificity5
MRI findings in neurologic Wilson disease include:67
- T2 hyperintensities in basal ganglia
- Central pontine myelinolysis-like changes
- Cerebral atrophy (advanced cases)
- Copper deposition visible on susceptibility-weighted imaging (7T MRI)
Current disease management still relies on:
- Copper chelation: Penicillamine, trientine
- Zinc salts: Block intestinal copper absorption
- Dietary copper restriction
- Liver transplantation: For acute liver failure or end-stage disease
ATP7B is also a direct target for emerging disease-modifying approaches:
- AAV-linked ATP7B gene replacement: Preclinical studies show durable correction of copper metabolism in murine models9
- Protein trans-splicing: Full-length ATP7B reconstitution through protein trans-splicing corrects Wilson disease in mice8
- Small molecule correctors: Pharmacologic enhancement of residual ATP7B function
- Copper chaperone modulation: Targeting ATOX1 or CCS to reduce toxic copper accumulation
Preclinical studies in murine models have demonstrated:
- Durable correction of copper metabolism after ATP7B restoration9
- 64Cu PET imaging can evaluate restoration of physiological copper excretion pathways10
- Successful rescue of hepatic copper accumulation
- Prevention of neurologic complications when treated early
The study of Atp7B Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- EASL-ERN, EASL-ERN Clinical Practice Guidelines on Wilson's Disease (2025)
- Członkowska A et al., Wilson disease (2018)
- Alkhouri N et al., Wilson disease: a summary of the updated AASLD Practice Guidance (2023)
- Bull PC et al., The Wilson disease gene is a putative copper-transporting P-type ATPase similar to the Menkes gene (1993)
- Djebrani-Oussedik N et al., Relative exchangeable copper: A highly specific and sensitive biomarker for Wilson disease diagnosis (2025)
- Jing XZ et al., Neuroimaging Correlates with Clinical Severity in Wilson Disease: A Multiparametric Quantitative Brain MRI (2024)
- Su D et al., Distinctive Pattern of Metal Deposition in Neurologic Wilson Disease: Insights From 7T Susceptibility-Weighted Imaging (2024)
- Padula A et al., Full-length ATP7B reconstituted through protein trans-splicing corrects Wilson disease in mice (2022)
- Murillo O et al., Long-term metabolic correction of Wilson's Disease in a murine model by gene therapy (2016)
- Murillo O et al., High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's Disease (2022)